		<u>j</u> -	
It is made available	under a CC-B	Y 4.0 International	license.

1	Three components of glucose dynamics – value, variability, and
2	autocorrelation – are independently associated with coronary plaque
3	vulnerability
4	
5	Authors
6	Hikaru Sugimoto, <sup>1</sup> Ken-ichi Hironaka, <sup>2</sup> Tomoko Yamada, <sup>3</sup> Natsu Otowa-Suematsu, <sup>3</sup> Yushi
7	Hirota, <sup>3</sup> Hiromasa Otake, <sup>4</sup> Ken-Ichi Hirata, <sup>3</sup> Kazuhiko Sakaguchi, <sup>3</sup> Wataru Ogawa, <sup>3*</sup> and
8	Shinya Kuroda <sup>1,2,5</sup> *
9	
10	Affiliations
11	<sup>1</sup> Department of Biochemistry and Molecular Biology, Graduate School of Medicine, The
12	University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
13	<sup>2</sup> Department of Biological Sciences, Graduate School of Science, The University of Tokyo,
14	7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
15	<sup>3</sup> Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University
16	Graduate School of Medicine, Kusunoki-cho 7-5-1, Chuo-ku, Kobe, Hyogo 650-0017, Japan
17	<sup>4</sup> Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University
18	Graduate School of Medicine, Kusunoki-cho 7-5-1, Chuo-ku, Kobe, Hyogo 650-0017, Japan
19	<sup>5</sup> Lead contact
20	
21	*Corresponding authors: Wataru Ogawa, ogawa@med.kobe-u.ac.jp; Shinya Kuroda,
22	skuroda@bs.s.u-tokvo.ac.ip

## 24 SUMMARY

25	Impaired glucose homeostasis leads to many complications, with coronary artery disease
26	(CAD) being a major contributor to healthcare costs. However, current CAD screening
27	methods lack efficacy. Here, we predicted CAD using easy-to-measure indices, including
28	continuous glucose monitoring (CGM)-derived indices. We found that CGM-derived indices,
29	particularly ADRR and AC_Var, exhibited stronger predictive capabilities for CAD
30	compared to commonly used diabetes diagnostic indices such as fasting blood glucose
31	(FBG), hemoglobin A1C (HbA1c), and plasma glucose level at 120 min during oral glucose
32	tolerance tests (PG120). Factor analysis identified three distinct components underlying
33	glucose dynamics - value, variability, and autocorrelation - each independently associated
34	with CAD. Remarkably, ADRR was influenced by the first two components, and AC_Var
35	was influenced by the third component. FBG, HbA1c, and PG120 were influenced only by
36	the value component, making them insufficient for CAD prediction. CGM-derived indices
37	reflecting the three components can outperform traditional diabetes diagnostic methods in
38	CAD prediction. (150/150 words)
39	
40	Keywords: Continuous glucose monitoring; oral glucose tolerance test; virtual histology-
41	intravascular ultrasound; coronary artery disease
42	

## 44 INTRODUCTION

Diabetes mellitus (DM) leads to a variety of complications, primarily caused by vascular 45 damage.<sup>1</sup> Among the complications, coronary artery disease (CAD) accounts for a large 46 fraction of the morbidity, mortality, and healthcare costs in patients with type 2 DM 47 (T2DM).<sup>2</sup> Various prognostic models<sup>1,3</sup> and diagnostic markers<sup>2</sup> have been developed to 48 predict CAD; however, screening of CAD can be ineffective, costly, or laborious.<sup>2,4</sup> More 49 effective approaches for identifying individuals at high risk for complications using readily 50 obtained clinical variables are warranted. 51 Blood glucose levels are among the readily obtained predictors of the 52 complications.<sup>5</sup> The disrupted conditions of glucose dynamics seen in impaired glucose 53 54 tolerance (IGT) and T2DM are partly characterized by high concentrations of blood glucose levels.<sup>6</sup> High concentrations of blood glucose levels have been defined as having high 55 hemoglobin A1c (HbA1c) levels, fasting blood glucose (FBG) levels, and plasma glucose 56 concentration at 120 min during the oral glucose tolerance test (OGTT) (PG120).<sup>6</sup> These 57 indices, especially HbA1c, are associated with complications of T2DM.<sup>7</sup> 58 59 Beyond the absolute value of glucose concentration, glucose variability also contributes to the prognosis of the complications<sup>5,6,8–11</sup> and all-cause mortality.<sup>12</sup> Continuous 60 glucose monitoring (CGM) can estimate short-term glycemic variability,<sup>13</sup> and is reportedly 61 able to predict T2DM complications.<sup>14</sup> Standard deviation (Std) of glucose levels 62 (CGM\_Std), mean amplitude of glycemic excursion (MAGE), mean of daily difference 63 (MODD), and continuous overlapping net glycemic action (CONGA) are established indices 64 of glycemic variability, of which CGM\_Std and MAGE are more highly correlated with 65 coronary plaque properties.<sup>15</sup> Among glucose level-related indices, including HbA1c and 66 FBG, MAGE is an independent determinant of coronary plaque instability.<sup>16</sup> 67 Other CGM-derived indices such as average daily risk ratio (ADRR), lability index 68 69 (LI), J-index, mean absolute glucose (MAG), and glycemic risk assessment in diabetes

equation (GRADE) have also been developed.<sup>17</sup> We recently showed that AC Mean and 70 AC\_Var, which are calculated from the autocorrelation function of glucose levels measured 71 by CGM, can detect decreased abilities in glucose regulation that cannot be captured by FBG, 72 HbA1c, or the other conventional CGM-derived indices.<sup>18</sup> The characteristics of glucose 73 dynamics can also be estimated from insulin concentrations. The disposition index (DI), 74 which is the product of insulin sensitivity and insulin secretion, reflects and predicts glycemic 75 disability beyond FBG.<sup>19</sup> Several other glucose-related indices have also been reported; 76 however, how these indices can be combined to deduce T2DM complications including CAD 77 has yet to be established. 78 The objectives of this study were to determine (1) which clinical parameters are 79 80 particularly useful in predicting CAD, (2) what factors underlie these indices, and (3) how these factors are associated with CAD. We investigated the characteristics of 14 CGM-81 derived indices: 12 relatively well-known CGM-derived indices<sup>17</sup> and 2 indices (AC\_Mean 82 and AC\_Var) as well as OGTT-derived indices, and investigated the relationship between 83 these parameters and coronary plaque vulnerability assessed by virtual histology-84 intravascular ultrasound (VH-IVAS), a strong predictor of coronary events. We showed that 85 CGM-derived indices are particularly useful in the prediction. In addition, we showed that 86 three components, namely, value, variability, and autocorrelation, underly blood glucose 87 level-related indices, and that the three are independently associated with coronary plaque 88 vulnerability. 89 90

91 **RESULTS** 

# 92 CGM\_Mean, CGM\_Std, and AC\_Var independently contribute to the prediction of 93 coronary plaque vulnerability

To characterize CGM-derived indices in estimating the risk of CAD, we examined
Spearman's correlation coefficients (*r*) between CGM-derived indices and the ratio of

necrotic core to total plaque volume (%NC) (Figs. 1A, S1). %NC, a widely used parameter of 96 plaque vulnerability, was assessed by VH-IVUS. We performed this analysis using a 97 previously described cohort consisting of 8 individuals with normal glucose tolerance (NGT), 98 16 with IGT, and 29 with T2DM.<sup>15</sup> For comparison, we also investigated FBG, HbA1c, 99 100 OGTT-derived indices, body mass index (BMI), triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), systolic blood pressure 101 102 (SBP), and diastolic BP (DBP). Twelve CGM-derived indices, namely, ADRR, MAGE, JINDEX, CGM\_Std (Std of 103 glucose levels measured by CGM), CGM\_Mean (mean glucose levels measured by CGM), 104 GRADE, MVALUE, AC\_Var, LI, HBGI, CONGA, and MODD, exhibited significant 105 106 correlations with %NC (Fig. 1A). By contrast, with the exception of the insulinogenic index (I.I.), OGTT-derived indices, as well as other indices including FBG and HbA1c, displayed 107 relatively weak correlations with %NC (Fig. 1A, blue, magenta, and green), suggesting that 108 CGM-derived indices are effective in predicting %NC. Of note, this study enrolled 109 individuals with well-controlled serum cholesterol and BP levels (Fig. S2). The weak 110 111 correlations between cholesterol and BP-related indices and %NC (Fig. 1A) do not mean that 112 cholesterol and BP are not associated with %NC. Consequently, our subsequent analysis focused primarily on indices unrelated to cholesterol and BP. 113 For a more comprehensive assessment of the association among clinical parameters, 114 we constructed a correlation network connecting relationships with Q < 0.05 (Fig. 1B). The Q 115 values were calculated by Spearman's correlation test followed by multiple testing 116 adjustment using the Benjamini-Hochberg method. The correlation network showed that 117

118 AC\_Var was statistically significantly correlated with %NC (r = 0.35; 95% confidence

interval [CI], 0.09–0.57) (Fig. 1B). By contrast, AC\_Var displayed relatively weak

120 correlations with other indices, including CGM\_Mean (r = -0.02; 95% CI, -0.30-0.24) and

121 CGM\_Std (*r* = 0.15; 95% CI, -0.14-0.43) (Fig. 1B, C).

122	We previously reported that AC_Var, calculated from the autocorrelation function of
123	glucose levels, can capture glucose handling capacities that cannot be captured by
124	conventional CGM-derived indices including CGM_Mean and CGM_Std. <sup>18</sup> Based on the
125	study, we hypothesized that AC_Var can identify individuals with high %NC independently
126	from CGM_Mean and CGM_Std. To test this hypothesis, we conducted multiple regression
127	analysis with CGM_Mean, CGM_Std, and AC_Var as input variables and %NC as the
128	objective variable (Fig. 1D). The variance inflation factor (VIF), an index of
129	multicollinearity, for CGM_Mean, CGM_Std, and AC_Var was 1.1, 1.1, and 1.0,
130	respectively, suggesting that CGM_Mean, CGM_Std, and AC_Var had low multicollinearity
131	with each other. The $R^2$ of the model that predicted %NC from the three indices was 0.36.
132	CGM_Mean, CGM_Std, and AC_Var had statistically significant independent positive
133	correlations with %NC (Fig. 1D), suggesting that CGM_Mean, CGM_Std, and AC_Var are
134	independently associated with %NC. Notably, the $R^2$ of the model that predicted %NC from
135	FBG, HbA1c, and PG120, which have been used as diagnostic markers of diabetes, was only
136	0.05 (Fig. 1D). Multivariate analyses including other indices also indicated that AC_Mean
137	and AC_Var had relatively low multicollinearity with other CGM-derived indices
138	(Supplementary text). Collectively, we conclude that CGM-derived indices are useful for
139	predicting %NC compared to indices used for diabetes diagnosis, and that CGM_Mean,
140	CGM_Std, and AC_Var independently contribute to the prediction of %NC.
141	

# CGM-derived indices, particularly ADRR, AC\_Var, MAGE, and LI are effective in predicting coronary plaque vulnerability

144 To avoid overfitting and investigate which input variables are particularly useful in

145 estimating %NC, we performed Least Absolute Shrinkage and Selection Operator (LASSO)

regression (Fig. 2).<sup>20</sup> LASSO uses L1 regularization to produce models with fewer

147 parameters and has been widely applied to feature selection in predictive modeling.<sup>21</sup> We

148	included BMI, FBG, HbA1c, OGTT-derived indices, and CGM-derived indices as the input
149	variables. The leave-one-out cross-validation identified the optimal regularization coefficient,
150	lambda, as 0.849 (Fig. 2A). At the lambda, the coefficients of ADRR, AC_Var, MAGE, and
151	LI were estimated to be non-zero coefficients (Fig. 2B, C), suggesting that CGM-derived
152	indices, particularly ADRR, AC_Var, MAGE, and LI, contribute to the prediction of %NC.
153	Even with the inclusion of SBP, DBP, TG, LDL-C, and HDL-C as additional input variables,
154	the results remained consistent, with the coefficients of ADRR, AC_Var, MAGE, and LI still
155	estimated as non-zero coefficients (Fig. S4).
156	To further validate the results of the LASSO, we also performed Partial Least
157	Squares (PLS) regression and investigated the VIP scores <sup>22</sup> (Fig. 2D). The VIP scores of
158	ADRR, AC_Var, MAGE, and LI, which were estimated to be non-zero coefficients by
159	LASSO, were higher than 1, indicating that these four variables especially contribute to the
160	prediction of %NC.
161	
162	Three components of dysglycemia – high value, high variability, and low
163	autocorrelation – are associated with coronary plaque vulnerability
164	To identify factors underlying the clinical parameters and investigate how these factors are
165	associated with %NC, we conducted exploratory factor analysis. Factor analysis reduces
166	interrelated indices into a smaller set of underlying common factors, and has been employed
167	to examine the interdependencies among various clinical parameters <sup>23–25</sup> and DM
168	complications. <sup>26</sup>
169	To determine the optimal number of underlying factors, we investigated Bayesian
170	information criterion (BIC) and minimum average partial (MAP) methods, indicating that
171	five or six factors were appropriate, respectively. We first set the number of underlying
172	factors as 5. Figure 3A indicates that FBG, HbA1c, PG120, I.I., oral DI, CGM Mean.

most of these indices are related to the value of blood glucose concentration, factor 1 was 174 labeled "value." CGM Std, MAGE, LI, MAG, MODD, JINDEX, and ADRR clustered as 175 factor 2. Given that these indices are related to glucose variability, factor 2 was labeled 176 "variability." Given that the definition of JINDEX is based on the sum of CGM Mean and 177 CGM Std, and that of ADRR is based on both high and low values of glucose, the result that 178 JINDEX and ADRR clustered in both factors 1 and 2 is plausible. Given that autocorrelation-179 derived indices, AC Mean and AC Var, clustered as factor 3, factor 3 was labeled 180 "autocorrelation." BMI, PG120, composite index, and oral DI clustered as factor 4. Factor 4 181 did not include any CGM-derived indices. Given that this combination of indices indicates a 182 decrease in oral DI and associated increase in blood glucose due to decreased insulin 183 184 sensitivity, factor 4 was labeled "sensitivity (without CGM)". PG120, I.I., oral DI, and MAG clustered as factor 5. Factor 5 did not have positive loadings of any CGM-derived indices. 185 Given that this combination of the indices indicates a decrease in oral DI and associated 186 increase in blood glucose due to decreased insulin secretion (I.I.), factor 5 was labeled 187 "secretion (without CGM)." The cumulative percentages of the total variance of the factors 188 were 39%, 60%, 70%, 75%, and 80%, respectively. 189

The validity of the factor analysis was assessed according to previous studies.<sup>23,26</sup> To 190 evaluate the applicability of the factor analysis, the Kaiser-Meyer-Olkin (KMO) and 191 Bartlett's spherical test were performed. The KMO test indicated that the value of the 192 measure of sampling adequacy for this data was 0.64, and Bartlett's spherical test indicated 193 that the variables were statistically significantly intercorrelated (P < 0.01), suggesting that 194 this dataset was applicable for the factor analysis. To evaluate internal consistency, 195 Cronbach's a (Fig. 3B) and item-total correlations were calculated for each factor. 196 Cronbach's a was 0.97 for factor 1, 0.93 for factor 2, 0.90 for factor 3, 0.72 for factor 4, and 197 198 0.66 for factor 5; these values were larger than 0.65 (Fig. 3B), suggesting that the internal 199 consistency was satisfactory. While Cronbach's a of factor 5 was relatively low, exclusion of

200 MAG increased the Cronbach's  $\alpha$  to 0.84, indicating that the association between factor 5 and decrease in oral DI and associated increase in blood glucose due to decreased insulin 201 secretion could be considered reliable. Item-total correlations ranged from 0.63 to 0.97 for 202 factor 1, 0.72 to 0.94 for factor 2, 0.82 for factor 3, 0.54 to 0.76 for factor 4, and 0.37 to 0.86 203 for factor 5. With the exception of MAG, item-total correlations ranged from 0.84 to 0.91 for 204 factor 5. The correlation coefficient of MAG was 0.37, which can be considered a modest 205 correlation,<sup>23</sup> and the item-total correlations were generally reasonably strong in 206 demonstrating reliability. 207

We also investigated a 6-factor solution (Fig. S5A). Factors 1, 2, and 3 could be 208 interpreted as value, variability, and autocorrelation, respectively, similar to the 5-factor 209 210 solution. Given that factor 6 had no factor loadings > 0.3, we applied the 5-factor solution in the subsequent analysis. Furthermore, the inclusion of SBP, DBP, TG, LDL-C, and HDL-C 211 into the input variables did not change the presence of the three components (value, 212 variability, and autocorrelation) in glucose dynamics (Fig. S5B). Since we only included only 213 individuals with well-controlled serum cholesterol and BP levels in this study, we applied the 214 5-factor solution without these indices (Fig. 3A) to the following analysis. 215

To further examine the stability of the results of the factor analysis, we also conducted hierarchical clustering analysis (Fig. S6). The optimal number of clusters was determined based on silhouette analysis. A large positive silhouette coefficient indicates that each cluster is compact and distinct from the others. The analysis indicated that the four clusters were appropriate (Fig. S6A). Clusters 1, 2, and 3 can be interpreted as value, variability, and autocorrelation, respectively (Fig. S6B). This confirmed the consistency of the clustering analysis with the factor analysis.

To investigate the reproducibility of the factor analysis, we conducted factor analyses using the previously reported datasets (Fig. S7). Factors that can be interpreted as value, variability, and autocorrelation were observed in both the Japanese<sup>18</sup> (Fig. S7A) and

American<sup>27</sup> (Fig. S7B) datasets, suggesting the reproducibility of glucose dynamics with these three components.

To investigate the association between these underlying factors and %NC, we investigated the correlation between the factor scores and %NC (Fig. 3C). The factor value and variability showed significant positive correlations with %NC, whereas autocorrelation showed a significant negative correlation. Factors 4 and 5, which were less related to the CGM-derived indices, showed weaker correlations with %NC. Collectively, we conclude that glucose dynamics has three components – value, variability, and autocorrelation – and that these three components are associated with %NC.

235

# Overview of the three components of dysglycemia: high value, high variability, and low autocorrelation

We showed the existence of three components of glucose dynamics: value, variability, and autocorrelation. We also showed that %NC tended to increase with higher value, higher variability, and lower autocorrelation. To investigate whether each component can be varied separately, and to overview the characteristics of glucose dynamics with different values of the components, we simulated glucose fluctuations using a previously reported mathematical model<sup>28</sup> (Figs. 4, S8).

We could generate glucose fluctuations with almost the same standard deviation 244 (Std) and AC\_Var but with a different mean (Fig. 4A). Similarly, we could also simulate 245 glucose fluctuations with almost the same mean and AC\_Var but different Std, and with 246 almost the same mean and Std but different AC\_Var. These three components could be 247 changed separately by changing the parameters within the range of values for NGT 248 individuals (Fig. S8B). Individuals with higher AC\_Var tended to have higher %NC (Fig. 1); 249 however, comparing the glucose dynamics with higher and lower AC\_Var, the maximum 250 251 value of blood glucose was lower in individuals with higher AC\_Var (Fig. 4A).

252	We also investigated the relationship between the three components and shapes of
253	the glucose response curve after OGTT. Patterns of the glucose response curve after OGTT
254	were heterogeneous, and four distinct patterns, denoted class 1-4, were previously identified
255	(Fig. 4B). <sup>29</sup> The classes with a high mean did not necessarily have high Std or AC_Var (Fig.
256	4C). The classes with high Std did not necessarily have high mean and AC_Var (Fig. 4C),
257	consistent with the result that mean, Std, and AC_Var had low multicollinearity with each
258	other. Compared to class 2, only class 1 was lower in mean and Std, and was higher in
259	AC_Var. Compared to class 2, only class 3 was higher in mean, Std, and AC_Var. Compared
260	to class 2, only class 4 was higher in mean and Std, and lower in AC_Var. Collectively, the
261	three components could characterize the previously reported four distinct patterns during
262	OGTT.

Class 3 was characterized by normal FBG and PG120 values, but is reportedly 263 associated with increased risk of diabetes and higher all-cause mortality rate, suggesting that 264 subgroups at high risk may not be identified by investigating only FBG and PG120.<sup>29</sup> Std and 265 AC\_Var were high in class 3 (Fig. 4C), suggesting that high Std and high AC\_Var indicate 266 glycemic disability independent of PG120. 267

268

#### DISCUSSION 269

Here, we showed the existence of three distinct components in glucose dynamics, namely 270 value, variability, and autocorrelation. We also showed that the higher the value, the higher 271 the variability; and the lower the autocorrelation, the more vulnerable the coronary plaque. 272 We previously reported that AC\_Var, an index reflecting autocorrelation, can detect 273 decreased abilities in glucose regulation independently of other CGM-derived indices 274 including CGM\_Mean and CGM\_Std, which reflect value and variability components, 275 respectively.<sup>18</sup> Diabetes diagnosis has been based on elevated FBG, PG120, and HbA1c 276 277 levels. However, these indices primarily reflect only the value component of glucose

dynamics, and consequently the predictive performance of prediction model for %NC using
FBG, PG120, and HbA1c was relatively modest compared to that of the model using all three
components of glucose dynamics. This result is partially consistent with a previous notion
that glucose dynamics include two components: amplitude and timing.<sup>30</sup> Collectively, for the
effective prediction of glycemic control capacity and diabetic complications, a
comprehensive examination of all three components (value, variability, and autocorrelation)
is imperative.

We also showed that CGM-derived indices, especially ADRR and AC\_Var, 285 contribute to the prediction of %NC by using LASSO (Fig. 2). Given that the definition 286 equation for ADRR is affected by both high and low concentrations of blood glucose,<sup>17</sup> it is 287 288 likely affected by both glucose concentration values and glycemic variability. Factor analysis (Fig. 3) also showed that ADRR clustered as both factor 1 (value) and factor 2 (variability). 289 Since three factors, value, variability, and autocorrelation, contribute independently to the 290 prediction of the complication, it would be useful to examine ADRR, which is influenced by 291 both value and variability, and AC\_Var, which is influenced by autocorrelation, in 292 293 predicting %NC with a minimal number of variables. Therefore, the result of the LASSO showing that ADRR and AC\_Var are particularly effective in predicting %NC is consistent 294 with the results of the factor analysis that the three components contribute to the prediction. 295

This study also provided evidence that autocorrelation can vary independently from 296 the value and variability components by using simulated data. As shown in Figure 4, these 297 three components could be varied independently by simply changing the parameters related 298 to glucose regulation within the range of NGT individuals. In addition, simulated glucose 299 dynamics indicated that even subjects with low autocorrelation did not necessarily have high 300 maximum and minimum blood glucose levels. This study also indicated that these three 301 302 components qualitatively corresponded to the four distinct glucose patterns observed after glucose administration, which were identified in a previous study.<sup>29</sup> Glycemic variability is 303

involved in T2DM complications by oxidative stress and endothelial dysfunction;<sup>6,31</sup> 304 however, the reasons why the three components, especially autocorrelation, independently 305 contribute to the prediction remain unknown. The underlying biological mechanisms and 306 effects of the three components on living systems need to be investigated in future studies. 307 The current study had several limitations. LASSO and factor analysis indicated that 308 CGM-related features were particularly important in predicting %NC. However, these results 309 do not mean that other clinical parameters do not associate with T2DM complications, 310 because we only included subjects with well-controlled serum cholesterol and BP levels in 311 this study. Moreover, a previous study indicated that components of interday variability and 312 hypoglycemia exist under CGM-derived indices,<sup>25</sup> but we did not observe these components. 313 This may be because the number of T2DM subjects was small and the measurement period 314 was short (2 days) in this study. Factor analyses of data with a longer measurement period 315 that include more patients with T1DM and T2DM could change the results. In addition, 316 although we used three different data sets with a total of 174 subjects, the sample size still 317 tended to be small to examine the relationship among the variables examined in this study. 318 319 Larger and prospective studies are required for a more accurate assessment of the variables in the prediction of the abnormality. 320

In conclusion, glucose dynamics has three components: value, variability, and autocorrelation. These three components are associated with coronary plaque vulnerability. CGM-derived indices reflecting these three components can be valuable predictive tools for T2DM complications, compared to conventional diabetes diagnostic markers reflecting only the value component. To facilitate this CGM-derived prediction, we created a web application that performs a multiple regression model with these three components as input variables (https://cgm-basedregression.streamlit.app/).

### 329 METHODS

### 330 Subjects and measurements

A previously reported dataset<sup>15</sup> was used in this study. The retrospective observational study 331 was approved by the ethics committee of Kobe University Graduate School of Medicine 332 (UMIN000018326; Kobe, Japan). Briefly, a 75-g OGTT, CGM, and percutaneous coronary 333 intervention (PCI) were carried out on 53 participants. Of note, with a type I error of 0.05, a 334 power of 0.8, and an expected correlation coefficient of 0.4, a sample size of 47 was required 335 to detect a significant difference from zero in the correlation coefficient. The iPro2 CGM 336 system (Medtronic, Northridge, CA, USA) was used, and data from the second and third days 337 of CGM were analyzed. During PCI, VH-IVUS was carried out to assess the plaque 338 components. 339 Participants aged 20-80 years with LDL-C levels < 120 mg/dL under statin 340 administration or <100 mg/dL under other treatments for dyslipidemia, including lifestyle 341 intervention, were included in this study. Participants with acute coronary syndrome, 342 unsuitable anatomy for virtual VH-IVUS, poor imaging by VH-IVUS, hemodialysis, 343 inflammatory disease, shock, low cardiac output, or concurrent malignant disease were 344 excluded from this study. 345

346

#### 347 Calculation of clinical indices

348 CGM-derived indices:

349 Fourteen CGM-derived indices were evaluated: 12 relatively well-known CGM-derived

350 indices<sup>17</sup> and 2 indices (AC\_Mean and AC\_Var), which were indicated to capture glucose

- handling capacities independently of the 12 indices.<sup>18</sup> AC\_Mean and AC\_Var are the mean
- and variance of the autocorrelation coefficients at lags 1–30, respectively. CGM\_Mean and
- 353 CGM\_Std indicate the mean value and Std of glucose levels measured by CGM, respectively.
- 354 CONGA, LI, JINDEX, HBGI, GRADE, MODD, MAGE, ADRR, MVALUE, and MAG

355	were calculated using EasyGV software. <sup>17</sup> The calculating formulae of these indices are
356	shown in Table S1. They were calculated from the CGM data measured every 5 min.

357

358 OGTT-derived indices:

Three OGTT-derived indices were calculated as previously described.<sup>15</sup> I.I. indicates insulin secretion, which can be calculated from the ratio of the increment of immunoreactive insulin (IRI) to that of plasma glucose at 30 min after onset of the OGTT. Composite index indicates insulin sensitivity, which can be calculated from fasting plasma glucose, fasting IRI, mean blood glucose levels, and mean serum IRI concentrations during the OGTT. Oral DI was calculated from the product of composite index and the ratio of the area under the insulin concentration curve from 0 to 120 min to that for plasma glucose from 0 to 120 min, without

366 367

368 VH-IVUS-derived index:

369 VH-IVUS was carried out using the Eagle Eye Platinum 3.5-Fr 20-MHz catheter (Volcano,

Rancho Cordova, CA, USA), as previously described.<sup>15</sup> The %NC, a widely used parameter

of plaque vulnerability, was evaluated.

372

### 373 Prediction models and statistical analyses

using the data measured at 90 min, in the OGTT.

374 In this study, we conducted multiple linear regression, LASSO regression, and PLS

regression. The input variables in these models included the following 26 variables: BMI,

376 SBP, DBP, TGs, LDL-C, HDL-C, FBG, HbA1c, PG120, I.I., composite index, oral DI,

377 CGM\_Mean, CGM\_Std, CONGA, LI, JINDEX, HBGI, GRADE, MODD, MAGE, ADRR,

378 MVALUE, MAG, AC\_Mean, and AC\_Var. In conducting these models, z-score

379 normalization on each input variable was performed.

380	The predictive performance of multiple linear regression was evaluated by the	

coefficient of determination ( $R^2$ ), the adjusted coefficient of determination (Adj  $R^2$ ), and AIC. The multicollinearity of the input variables was estimated by VIF. LASSO regression is a kind of linear regression with L1 regularization.<sup>20</sup> The optimal regularization coefficient, lambda, was based on leave-one-out cross-validation and mean-squared error. The importance of the input variables in predicting %NC was evaluated by the VIP scores<sup>22</sup> that were generated from PLS regression. These models were conducted using scikit-learn, a python-based tool kit.

388Relationships among indices were also evaluated using Spearman's correlation389coefficients (r), and the correlation coefficients were reported with 95% CIs through390bootstrap resampling. The number of resamples performed to form the distribution was set at39110000. Benjamini–Hochberg's multiple comparison test was also performed with a392significance threshold of Q < 0.05.</td>

393

## 394 Factor analysis and hierarchical clustering analysis

395 The intercorrelations of the clinical parameters and their associations with %NC were assessed using exploratory factor analyses and hierarchical clustering analyses. We followed 396 the previously reported approach<sup>23,24,26,32</sup> with some modifications in conducting our 397 exploratory factor analyses. BIC and MAP methods were used to determine the number of 398 underlying factors. Variables with factor loadings of  $\geq 0.30$  were used in interpretation. To 399 improve the interpretation, orthogonal (varimax) rotation was used. To evaluate the 400 applicability of the factor analysis, KMO and Bartlett's spherical test were performed. To 401 evaluate internal consistency of each factor, Cronbach's a and item-total correlations were 402 calculated. The association of the factor scores with %NC was assessed using Spearman's 403 correlation. 404

Hierarchical clustering analysis was conducted using a method that combines a
Euclidean distance measure and Ward linkage. It was adopted after Z score normalization.
I.I., composite index, oral DI, and AC\_Mean were inverted negatively so that the value of
indices increased in subjects with abnormalities. The quality of the hierarchical clustering
analysis was evaluated based on silhouette analysis.<sup>33</sup>

410

## 411 Mathematical model used for simulating the characteristics of glucose dynamics

412 In simulating the characteristics of glucose dynamics, we used a simple and stable model, $^{28}$ 

413 which can be written as follows:

414 
$$\frac{dG}{dt} = -k_{\rm glu}G - k_{\rm sen}IG + k_{\rm pro} + f$$

$$\frac{dI}{dt} = \frac{k_{\text{sec}}}{k_{\text{tim}}} \int_{t-k_{\text{tim}}}^{t} G \, ds - k_{\text{cle}} I$$

where the variables *G* and *I* denote blood glucose and insulin concentrations, respectively. We simulated 240 min profiles of *G*, and calculated the mean, Std, and AC\_Var of *G*. The parameters were changed within the range participants could take.<sup>28</sup> Five mg/dL/min glucose was applied for 10 min at 30 min as the external input of glucose f (Fig. S8A).

420

## 421 Characterization of glucose patterns during the OGTT

422 We investigated the characteristics of previously reported glucose patterns during the

423 OGTT.<sup>29</sup> In the study, 5861 subjects without diabetes underwent the OGTT with

424 measurements of glucose levels at three time points (0, 30, and 120 min), and four distinct

425 glucose patterns associated with long-term outcomes including diabetes onset, CVD, and all-

- 426 cause mortality rate were identified. For the calculation of mean, Std, and AC\_Var of glucose
- 427 levels, each time point was linearly imputed. Here, AC\_Var was calculated from the
- 428 autocorrelation function at lags 1–20, as we had glucose data available for only 2 h after the

429 OGTT.

#### 430

#### **RESOURCE AVAILABILITY** 431

#### Lead contact 432

- For any additional information and requests regarding resources and reagents, please contact 433
- the lead contact, Shinya Kuroda (skuroda@bs.s.u-tokyo.ac.jp). 434

#### Data and code availability 435

- The CGM data that support the findings of this study are available from the GitHub 436
- repository (https://github.com/HikaruSugimoto/CGM regression app). The code that 437
- calculates AC Mean and AC Var and that performs regression analysis with CGM-derived 438
- indices as input variables are available from the repository 439
- (https://github.com/HikaruSugimoto/CGM\_regression\_app) and the web application 440
- 441 (https://cgm-basedregression.streamlit.app/).
- Materials availability 442
- The study did not generate any new material. 443
- Acknowledgments 444
- 445 Personal Thanks. We thank our laboratory members for critically reading this manuscript
- Author Contributions. H.S. analyzed the data. H.S., K.H., T.Y., N.O.S., Y.H., H.O., K.H., 446
- K.S., W.O., and S.K. wrote the manuscript. W.O. and S.K. supervised the study. 447
- Conflict of Interest. The authors have no conflicts of interest to declare. 448
- Funding and Assistance. This study was supported by the Japan Society for the Promotion 449
- of Science (JSPS) KAKENHI (JP21H04759), CREST, the Japan Science and Technology 450
- Agency (JST) (JPMJCR2123), and The Uehara Memorial Foundation. 451

#### **Figures** 453





- 456 (A) The absolute values of Spearman's correlation coefficients between clinical parameters457 and %NC. Bars represent the 95% CIs.
- (B) A spring layout of the correlation network involving %NC (black), 14 CGM-derived
- 459 indices (red), 3 blood glucose level-related indices (magenta), 3 insulin sensitivity or
- 460 secretion-related indices (blue), and 6 other clinical indices (green) obtained from a single
- blood test or physical measurement. Connections denote relationships with Q < 0.05. The
- 462 width of the edges is proportional to the corresponding correlation coefficient.
- 463 (C) Scatter plots for AC\_Var versus CGM\_Mean (the left), and AC\_Var versus CGM\_Std
- 464 (the right). Each point corresponds to the values for a single subject. Subjects were colored
- based on the value of %NC. *r* is Spearman's correlation coefficient, and the value in
- 466 parentheses is 95% CI.
- 467 (D) Multiple regression analysis between %NC and CGM\_Mean, CGM\_Std, and AC\_Var
- 468 (the left). That between %NC and FBG, HbA1c, and PG120 (the right). Bars represent the
- 469 95% CIs of the coefficients.
- 470



## 471

#### Figure 2. LASSO and PLS regression analyses for predicting %NC. 472

(A) Relationship between regularization coefficients (lambda) and the MSE based on the 473

leave-one-out cross-validation in predicting %NC. Dotted vertical line indicates the optimal 474

lambda, which provides the least MSE. The optimal lambda was 0.849. 475

(B) LASSO regularization paths along the lambda in predicting %NC. Cyan, magenta, and 476

gray lines indicate the estimated coefficients of AC\_Mean, AC\_Var, and the other input 477

variables, respectively. Dotted vertical line indicates the optimal lambda. 478

(C) Estimated coefficients with the optimal lambda. Only variables with non-zero coefficients 479

- are shown. Input variables include the following 21 variables: BMI, FBG, HbA1c, PG120, 480
- I.I., composite index, oral DI, CGM\_Mean, CGM\_Std, CONGA, LI, JINDEX, HBGI, 481
- GRADE, MODD, MAGE, ADRR, MVALUE, MAG, AC\_Mean, and AC\_Var. 482

- (D) VIP generated from the PLS regression predicting %NC. Variables with a VIP  $\geq 1$  (the 483
- dotted line) were considered to significantly contribute to the prediction. 484

A							С	r = 0.30 (0.02 - 0.54)
								40
BMI	0.11	0.11	0.19	0.51	0.12	<b>1</b>		
FBG	0.74	0.03	0.12	0.15	0.15			استغنينية المديح
HDA1C	0.69	0.11	0.2	0.21	0.15			§ 20
PG120	0.6	0.21	0.08	0.35	0.54			
LL. Composite index	-0.47	-0.08	0.03	-0.21	-0.00			o
Composite index	-0.04	-0	0.03	-0.42	0.03	-1		-3 0 3
CGM Mean	-0.01	0.13	-0.01	-0.00	-0.59			1, Value
CONCA	0.55	0.13	0.01	0.07	0.05			
HRGI	0.00	0.02	-0	0.04	0.06			r = 0.29 (0.01 - 0.53)
MVALUE	0.99	0.1	0	0.07	0.00			40 -
GRADE	0.95	0.14	0.06	0.12	-0			· · · ·
CGM SH	0.21	0.95	0.00	-0.05	0.14			9
MAGE	0.19	0.85	-0.14	0.01	0.14			20 <b></b>
11	-0.01	0.85	-0.27	0.05	-0.09			
MAG	-0	0.87	-0.3	0.17	-0.36			0
MODD	0.15	0.72	0.21	0.09	0.06			-3 0 3
JINDEX	0.89	0.44	0.07	0.02	0.07			2, Variability
ADRR	0.68	0.63	-0.1	0.06	0.14			
AC Mean	0.23	-0.05	0.88	0.02	0.18		1	r = -0.29 (-0.520.0)
AC Var	0	0.19	-0.94	-0.13	0.18			40
	Vally Jan 2. Valle 3. A	pline utocorrel nsitivity (	and	Shart out	Gr.			20 0 -3 3, Autocorrelation
-		-						r = -0.02 (-0.31 - 0.23)
в			Cro	onbach	's α			40
1, \ 2, Varia 3, Autocorrel 4, Sensitivity (without C 5, Secretion (without C	Value ability ation GM) GM) (	o	.2 0	. <del> -</del> ).4 0	.6 0	₩ ₩ ₩ 1 1 .8 1.0		$ \begin{array}{c}                                     $
								. I

0 3 1, Value 0.29 (0.01-0.53) 0 3 2, Variability 29 (-0.52--0.02) 0 з 3, Autocorrelation ).02 (-0.31-0.28) 0 3 nsitivity (without CGM) .17(-0.12-0.42)-3 0 3

5, Secretion (without CGM)

Figure 3. Factor analysis of the clinical parameters. 487

- 488 (A) Factor analysis after orthogonal rotation. The values and colors were based on the factor
- 489 loadings. The columns represent each factor. The rows represent input indices.
- 490 (B) Cronbach's  $\alpha$  for each factor. Bars represent the 95% CI.
- 491 (C) Scatter plots and fitted linear regression lines for factor scores versus %NC. Each point
- 492 corresponds to the values for a single subject. *r* is Spearman's correlation coefficient, and the
- 493 value in parentheses is the 95% CI.





Figure 4. Overview of the three components of glucose dynamics. 496

(A) 240 min simulated glucose concentration. The colors of the line are based on the mean 497 value (Mean), Std, and AC\_Var of the simulated blood glucose. Red and gray dotted 498 horizontal lines indicate the minimum or maximum values of blood glucose, respectively. 499

- 500 (B) Previously reported patterns of blood glucose during the OGTT.<sup>29</sup> Green, class 1; light
- 501 blue, class 2; dark blue, class 3; red, class 4.
- 502 (C) Mean, Std, and AC\_Var of the glucose during the OGTT. Colors are based on the class
- shown in Figure 4B.

504

#### 506 References

- Fiarni, C., Sipayung, E. M. & Maemunah, S. Analysis and Prediction of Diabetes 1. 507 Complication Disease using Data Mining Algorithm. Procedia Comput. Sci. 161, 449-508 457 (2019). 509
- Bax, J. J. et al. Screening for coronary artery disease in patients with diabetes. Diabetes 510 2. Care 30, 2729–2736 (2007). 511
- Ravaut, M. et al. Predicting adverse outcomes due to diabetes complications with 3. 512 machine learning using administrative health data. NPJ Digit Med 4, 24 (2021). 513
- 514 4. Young, L. H. et al. Cardiac outcomes after screening for asymptomatic coronary artery 515 disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 301, 1547-1555 (2009). 516
- Psoma, O., Makris, M., Tselepis, A. & Tsimihodimos, V. Short-term Glycemic 5. 517 Variability and Its Association With Macrovascular and Microvascular Complications in 518 Patients With Diabetes. J. Diabetes Sci. Technol. 19322968221146810 (2022). 519
- Monnier, L., Colette, C. & Owens, D. R. Glycemic variability: the third component of 520 6. the dysglycemia in diabetes. Is it important? How to measure it? J. Diabetes Sci. 521 Technol. 2, 1094–1100 (2008). 522
- 7. Selvin, E. et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic 523 adults. N. Engl. J. Med. 362, 800-811 (2010). 524
- 525 8. Gorst, C. et al. Long-term Glycemic Variability and Risk of Adverse Outcomes: A Systematic Review and Meta-analysis. Diabetes Care 38, 2354–2369 (2015). 526
- Zhou, J. J., Schwenke, D. C., Bahn, G., Reaven, P. & VADT Investigators. Glycemic 9. 527 Variation and Cardiovascular Risk in the Veterans Affairs Diabetes Trial. Diabetes Care 528 41, 2187–2194 (2018). 529
- 530 10. Gerbaud, E. et al. Glycemic Variability Is a Powerful Independent Predictive Factor of Midterm Major Adverse Cardiac Events in Patients With Diabetes With Acute Coronary 531 Syndrome. Diabetes Care 42, 674–681 (2019). 532
- 11. Su, G. et al. Association of glycemic variability and the presence and severity of 533 coronary artery disease in patients with type 2 diabetes. *Cardiovasc. Diabetol.* **10**, 19 534 (2011). 535
- 12. Cai, J. et al. Impact of the complexity of glucose time series on all-cause mortality in 536 patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 108, 1093-1100 (2023). 537
- 13. Service, F. J. Glucose variability. *Diabetes* 62, 1398–1404 (2013). 538
- 14. Tang, X. et al. Glycemic variability evaluated by continuous glucose monitoring system 539 is associated with the 10-y cardiovascular risk of diabetic patients with well-controlled 540
- HbA1c. Clin. Chim. Acta 461, 146-150 (2016). 541

porpotait	· <b>y</b> ·	•
It is made available under a CC-B	Ϋ́	4.0 International license .

<ol> <li>Otowa-suenasa, N. <i>et al.</i> Comparison of the relationship octive infinity parameters of glycemic variability and coronary plaque vulnerability assessed by virtual histology- intravascular ultrasound. <i>J. Diabetes Investig.</i> 9, 610–615 (2018).</li> <li>Okada, K. <i>et al.</i> Association between blood glucose variability and coronary plaque instability in patients with acute coronary syndromes. <i>Cardiovasc. Diabetol.</i> 14, 111 (2015).</li> <li>Hill, N. R. <i>et al.</i> Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. <i>Diabetes Technol. Ther.</i> 13, 921–928 (2011).</li> <li>Sugimoto, H. <i>et al.</i> Improved Detection of Decreased Glucose Handling Capacities via Novel Continuous Glucose Monitoring-Derived Indices: AC_Mean and AC_Var. <i>medRxiv</i> 2023–2009 (2023).</li> <li>Utzschneider, K. M. <i>et al.</i> Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. <i>Diabetes Care</i> 32, 335–341 (2009).</li> <li>Tibshirani, R. Regression shrinkage and selection via the lasso. <i>J. R. Stat. Soc.</i> 58, 267– 288 (1996).</li> <li>Wei, H. <i>et al.</i> Environmental chemical exposure dynamics and machine learning-based prediction of diabetes mellitus. <i>Sci. Total Environ.</i> 806, 150674 (2022).</li> <li>Wold, S., Sjöström, M. &amp; Eriksson, L. PLS-regression: a basic tool of chemometrics. <i>Chemometrics Intellig. Lab. Syst.</i> 58, 109–130 (2001).</li> <li>Cappelleri, J. C., Gerber, R. A., Kourides, I. A. &amp; Gelfand, R. A. Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1 diabetes. <i>Diabetes Care</i> 23, 1799–1803 (2000).</li> </ol>
<ul> <li><sup>545</sup> bi gjycenite variability and coronary plaque vulnerability assessed by virtual instology-</li> <li><sup>546</sup> intravascular ultrasound. <i>J. Diabetes Investig.</i> 9, 610–615 (2018).</li> <li><sup>547</sup> Okada, K. <i>et al.</i> Association between blood glucose variability and coronary plaque</li> <li><sup>548</sup> instability in patients with acute coronary syndromes. <i>Cardiovasc. Diabetol.</i> 14, 111 (2015).</li> <li><sup>549</sup> Hill, N. R. <i>et al.</i> Normal reference range for mean tissue glucose and glycemic</li> <li><sup>549</sup> variability derived from continuous glucose monitoring for subjects without diabetes in</li> <li><sup>550</sup> different ethnic groups. <i>Diabetes Technol. Ther.</i> 13, 921–928 (2011).</li> <li><sup>551</sup> 18. Sugimoto, H. <i>et al.</i> Improved Detection of Decreased Glucose Handling Capacities via</li> <li><sup>552</sup> Novel Continuous Glucose Monitoring-Derived Indices: AC_Mean and AC_Var.</li> <li><sup>553</sup> <i>medRxiv</i> 2023–2009 (2023).</li> <li><sup>554</sup> 19. Utzschneider, K. M. <i>et al.</i> Oral disposition index predicts the development of future</li> <li><sup>555</sup> diabetes above and beyond fasting and 2-h glucose levels. <i>Diabetes Care</i> 32, 335–341 (2009).</li> <li><sup>557</sup> 20. Tibshirani, R. Regression shrinkage and selection via the lasso. <i>J. R. Stat. Soc.</i> 58, 267–288 (1996).</li> <li><sup>559</sup> 21. Wei, H. <i>et al.</i> Environmental chemical exposure dynamics and machine learning-based</li> <li><sup>560</sup> prediction of diabetes mellitus. <i>Sci. Total Environ.</i> 806, 150674 (2022).</li> <li><sup>561</sup> 22. Wold, S., Sjöström, M. &amp; Eriksson, L. PLS-regression: a basic tool of chemometrics.</li> <li><sup>562</sup> <i>Chemometrics Intellig. Lab. Syst.</i> 58, 109–130 (2001).</li> <li><sup>563</sup> 23. Cappelleri, J. C., Gerber, R. A., Kourides, I. A. &amp; Gelfand, R. A. Development and</li> <li><sup>564</sup> factor analysis of a questionnaire to measure patient satisfaction with injected and</li> <li><sup>565</sup> inhaled insulin for type 1 diabetes. <i>Diabetes Care</i> 23, 1799–1803 (2000).</li> </ul>
<ul> <li>16. Okada, K. <i>et al.</i> Association between blood glucose variability and coronary plaque instability in patients with acute coronary syndromes. <i>Cardiovasc. Diabetol.</i> 14, 111 (2015).</li> <li>17. Hill, N. R. <i>et al.</i> Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. <i>Diabetes Technol. Ther.</i> 13, 921–928 (2011).</li> <li>18. Sugimoto, H. <i>et al.</i> Improved Detection of Decreased Glucose Handling Capacities via Novel Continuous Glucose Monitoring-Derived Indices: AC_Mean and AC_Var. <i>medRxiv</i> 2023–2009 (2023).</li> <li>19. Utzschneider, K. M. <i>et al.</i> Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. <i>Diabetes Care</i> 32, 335–341 (2009).</li> <li>20. Tibshirani, R. Regression shrinkage and selection via the lasso. <i>J. R. Stat. Soc.</i> 58, 267– 288 (1996).</li> <li>21. Wei, H. <i>et al.</i> Environmental chemical exposure dynamics and machine learning-based prediction of diabetes mellitus. <i>Sci. Total Environ.</i> 806, 150674 (2022).</li> <li>22. Wold, S., Sjöström, M. &amp; Eriksson, L. PLS-regression: a basic tool of chemometrics. <i>Chemometrics Intellig. Lab. Syst.</i> 58, 109–130 (2001).</li> <li>23. Cappelleri, J. C., Gerber, R. A., Kourides, I. A. &amp; Gelfand, R. A. Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1 diabetes. <i>Diabetes Care</i> 23, 1799–1803 (2000).</li> </ul>
<ol> <li>Okada, K. <i>et al.</i> Association between blood glucose variability and coronary plaque instability in patients with acute coronary syndromes. <i>Cardiovasc. Diabetol.</i> 14, 111 (2015).</li> <li>Hill, N. R. <i>et al.</i> Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. <i>Diabetes Technol. Ther.</i> 13, 921–928 (2011).</li> <li>Sugimoto, H. <i>et al.</i> Improved Detection of Decreased Glucose Handling Capacities via Novel Continuous Glucose Monitoring-Derived Indices: AC_Mean and AC_Var. <i>medRxiv</i> 2023–2009 (2023).</li> <li>Utzschneider, K. M. <i>et al.</i> Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. <i>Diabetes Care</i> 32, 335–341 (2009).</li> <li>Tibshirani, R. Regression shrinkage and selection via the lasso. <i>J. R. Stat. Soc.</i> 58, 267– 288 (1996).</li> <li>Wei, H. <i>et al.</i> Environmental chemical exposure dynamics and machine learning-based prediction of diabetes mellitus. <i>Sci. Total Environ.</i> 806, 150674 (2022).</li> <li>Wold, S., Sjöström, M. &amp; Eriksson, L. PLS-regression: a basic tool of chemometrics. <i>Chemometrics Intellig. Lab. Syst.</i> 58, 109–130 (2001).</li> <li>Cappelleri, J. C., Gerber, R. A., Kourides, I. A. &amp; Gelfand, R. A. Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1 diabetes. <i>Diabetes Care</i> 23, 1799–1803 (2000).</li> </ol>
<ul> <li>17. Hill, N. R. <i>et al.</i> Normal reference range for mean tissue glucose and glycemic</li> <li>variability derived from continuous glucose monitoring for subjects without diabetes in</li> <li>different ethnic groups. <i>Diabetes Technol. Ther.</i> 13, 921–928 (2011).</li> <li>18. Sugimoto, H. <i>et al.</i> Improved Detection of Decreased Glucose Handling Capacities via</li> <li>Novel Continuous Glucose Monitoring-Derived Indices: AC_Mean and AC_Var.</li> <li><i>medRxiv</i> 2023–2009 (2023).</li> <li>19. Utzschneider, K. M. <i>et al.</i> Oral disposition index predicts the development of future</li> <li>diabetes above and beyond fasting and 2-h glucose levels. <i>Diabetes Care</i> 32, 335–341</li> <li>(2009).</li> <li>20. Tibshirani, R. Regression shrinkage and selection via the lasso. <i>J. R. Stat. Soc.</i> 58, 267–288 (1996).</li> <li>21. Wei, H. <i>et al.</i> Environmental chemical exposure dynamics and machine learning-based</li> <li>prediction of diabetes mellitus. <i>Sci. Total Environ.</i> 806, 150674 (2022).</li> <li>22. Wold, S., Sjöström, M. &amp; Eriksson, L. PLS-regression: a basic tool of chemometrics.</li> <li><i>Chemometrics Intellig. Lab. Syst.</i> 58, 109–130 (2001).</li> <li>23. Cappelleri, J. C., Gerber, R. A., Kourides, I. A. &amp; Gelfand, R. A. Development and</li> <li>factor analysis of a questionnaire to measure patient satisfaction with injected and</li> <li>inhaled insulin for type 1 diabetes. <i>Diabetes Care</i> 23, 1799–1803 (2000).</li> </ul>
<ul> <li>(2013).</li> <li>(2013).</li> <li>(2013).</li> <li>(2013).</li> <li>(2013).</li> <li>(2013).</li> <li>(2013).</li> <li>(2013).</li> <li>(2013).</li> <li>(2014).</li> <li>(2015).</li> <li>(2015).</li> <li>(2015).</li> <li>(2015).</li> <li>(2015).</li> <li>(2017).</li> &lt;</ul>
<ul> <li>17. Fini, N. K. <i>et al.</i> Normal reference range for mean ussue grucose and grycenne variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. <i>Diabetes Technol. Ther.</i> 13, 921–928 (2011).</li> <li>18. Sugimoto, H. <i>et al.</i> Improved Detection of Decreased Glucose Handling Capacities via Novel Continuous Glucose Monitoring-Derived Indices: AC_Mean and AC_Var. <i>medRxiv</i> 2023–2009 (2023).</li> <li>19. Utzschneider, K. M. <i>et al.</i> Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. <i>Diabetes Care</i> 32, 335–341 (2009).</li> <li>20. Tibshirani, R. Regression shrinkage and selection via the lasso. <i>J. R. Stat. Soc.</i> 58, 267–288 (1996).</li> <li>21. Wei, H. <i>et al.</i> Environmental chemical exposure dynamics and machine learning-based prediction of diabetes mellitus. <i>Sci. Total Environ.</i> 806, 150674 (2022).</li> <li>22. Wold, S., Sjöström, M. &amp; Eriksson, L. PLS-regression: a basic tool of chemometrics. <i>Chemometrics Intellig. Lab. Syst.</i> 58, 109–130 (2001).</li> <li>23. Cappelleri, J. C., Gerber, R. A., Kourides, I. A. &amp; Gelfand, R. A. Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1 diabetes. <i>Diabetes Care</i> 23, 1799–1803 (2000).</li> </ul>
<ul> <li>variability derived from commons gracose momenting for subjects without diabetes in different ethnic groups. <i>Diabetes Technol. Ther.</i> 13, 921–928 (2011).</li> <li>Sugimoto, H. <i>et al.</i> Improved Detection of Decreased Glucose Handling Capacities via Novel Continuous Glucose Monitoring-Derived Indices: AC_Mean and AC_Var.</li> <li><i>medRxiv</i> 2023–2009 (2023).</li> <li>Utzschneider, K. M. <i>et al.</i> Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. <i>Diabetes Care</i> 32, 335–341 (2009).</li> <li>Tibshirani, R. Regression shrinkage and selection via the lasso. <i>J. R. Stat. Soc.</i> 58, 267– 288 (1996).</li> <li>Wei, H. <i>et al.</i> Environmental chemical exposure dynamics and machine learning-based prediction of diabetes mellitus. <i>Sci. Total Environ.</i> 806, 150674 (2022).</li> <li>Wold, S., Sjöström, M. &amp; Eriksson, L. PLS-regression: a basic tool of chemometrics. <i>Chemometrics Intellig. Lab. Syst.</i> 58, 109–130 (2001).</li> <li>Cappelleri, J. C., Gerber, R. A., Kourides, I. A. &amp; Gelfand, R. A. Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1 diabetes. <i>Diabetes Care</i> 23, 1799–1803 (2000).</li> </ul>
<ul> <li>18. Sugimoto, H. <i>et al.</i> Improved Detection of Decreased Glucose Handling Capacities via Novel Continuous Glucose Monitoring-Derived Indices: AC_Mean and AC_Var.</li> <li><i>medRxiv</i> 2023–2009 (2023).</li> <li>19. Utzschneider, K. M. <i>et al.</i> Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. <i>Diabetes Care</i> 32, 335–341 (2009).</li> <li>20. Tibshirani, R. Regression shrinkage and selection via the lasso. <i>J. R. Stat. Soc.</i> 58, 267– 288 (1996).</li> <li>21. Wei, H. <i>et al.</i> Environmental chemical exposure dynamics and machine learning-based prediction of diabetes mellitus. <i>Sci. Total Environ.</i> 806, 150674 (2022).</li> <li>22. Wold, S., Sjöström, M. &amp; Eriksson, L. PLS-regression: a basic tool of chemometrics. <i>Chemometrics Intellig. Lab. Syst.</i> 58, 109–130 (2001).</li> <li>23. Cappelleri, J. C., Gerber, R. A., Kourides, I. A. &amp; Gelfand, R. A. Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1 diabetes. <i>Diabetes Care</i> 23, 1799–1803 (2000).</li> </ul>
<ol> <li>Sugmitolo, H. <i>et al.</i> Improved Detection of Decreased Oncose Handning Capacities via Novel Continuous Glucose Monitoring-Derived Indices: AC_Mean and AC_Var. <i>medRxiv</i> 2023–2009 (2023).</li> <li>Utzschneider, K. M. <i>et al.</i> Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. <i>Diabetes Care</i> 32, 335–341 (2009).</li> <li>Tibshirani, R. Regression shrinkage and selection via the lasso. <i>J. R. Stat. Soc.</i> 58, 267– 288 (1996).</li> <li>Wei, H. <i>et al.</i> Environmental chemical exposure dynamics and machine learning-based prediction of diabetes mellitus. <i>Sci. Total Environ.</i> 806, 150674 (2022).</li> <li>Wold, S., Sjöström, M. &amp; Eriksson, L. PLS-regression: a basic tool of chemometrics. <i>Chemometrics Intellig. Lab. Syst.</i> 58, 109–130 (2001).</li> <li>Cappelleri, J. C., Gerber, R. A., Kourides, I. A. &amp; Gelfand, R. A. Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1 diabetes. <i>Diabetes Care</i> 23, 1799–1803 (2000).</li> </ol>
<ul> <li><i>medRxiv</i> 2023–2009 (2023).</li> <li>Utzschneider, K. M. <i>et al.</i> Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. <i>Diabetes Care</i> 32, 335–341 (2009).</li> <li>Tibshirani, R. Regression shrinkage and selection via the lasso. <i>J. R. Stat. Soc.</i> 58, 267–288 (1996).</li> <li>Wei, H. <i>et al.</i> Environmental chemical exposure dynamics and machine learning-based prediction of diabetes mellitus. <i>Sci. Total Environ.</i> 806, 150674 (2022).</li> <li>Wold, S., Sjöström, M. &amp; Eriksson, L. PLS-regression: a basic tool of chemometrics. <i>Chemometrics Intellig. Lab. Syst.</i> 58, 109–130 (2001).</li> <li>Cappelleri, J. C., Gerber, R. A., Kourides, I. A. &amp; Gelfand, R. A. Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1 diabetes. <i>Diabetes Care</i> 23, 1799–1803 (2000).</li> </ul>
<ul> <li><i>medRxiv</i> 2023–2009 (2023).</li> <li>Utzschneider, K. M. <i>et al.</i> Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. <i>Diabetes Care</i> 32, 335–341 (2009).</li> <li>Tibshirani, R. Regression shrinkage and selection via the lasso. <i>J. R. Stat. Soc.</i> 58, 267–288 (1996).</li> <li>Wei, H. <i>et al.</i> Environmental chemical exposure dynamics and machine learning-based prediction of diabetes mellitus. <i>Sci. Total Environ.</i> 806, 150674 (2022).</li> <li>Wold, S., Sjöström, M. &amp; Eriksson, L. PLS-regression: a basic tool of chemometrics. <i>Chemometrics Intellig. Lab. Syst.</i> 58, 109–130 (2001).</li> <li>Cappelleri, J. C., Gerber, R. A., Kourides, I. A. &amp; Gelfand, R. A. Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1 diabetes. <i>Diabetes Care</i> 23, 1799–1803 (2000).</li> </ul>
<ol> <li>Utzschneider, K. M. <i>et al.</i> Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. <i>Diabetes Care</i> 32, 335–341 (2009).</li> <li>Tibshirani, R. Regression shrinkage and selection via the lasso. <i>J. R. Stat. Soc.</i> 58, 267– 288 (1996).</li> <li>Wei, H. <i>et al.</i> Environmental chemical exposure dynamics and machine learning-based prediction of diabetes mellitus. <i>Sci. Total Environ.</i> 806, 150674 (2022).</li> <li>Wold, S., Sjöström, M. &amp; Eriksson, L. PLS-regression: a basic tool of chemometrics. <i>Chemometrics Intellig. Lab. Syst.</i> 58, 109–130 (2001).</li> <li>Cappelleri, J. C., Gerber, R. A., Kourides, I. A. &amp; Gelfand, R. A. Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1 diabetes. <i>Diabetes Care</i> 23, 1799–1803 (2000).</li> <li>Oh L-Y. Hong, X. S. Sung, X - A. &amp; Barrett Conner, E. Pravalence and factor analysis</li> </ol>
<ul> <li>diabetes above and beyond fasting and 2-h glucose levels. <i>Diabetes Care</i> 32, 335–341 (2009).</li> <li>20. Tibshirani, R. Regression shrinkage and selection via the lasso. <i>J. R. Stat. Soc.</i> 58, 267–288 (1996).</li> <li>21. Wei, H. <i>et al.</i> Environmental chemical exposure dynamics and machine learning-based prediction of diabetes mellitus. <i>Sci. Total Environ.</i> 806, 150674 (2022).</li> <li>22. Wold, S., Sjöström, M. &amp; Eriksson, L. PLS-regression: a basic tool of chemometrics. <i>Chemometrics Intellig. Lab. Syst.</i> 58, 109–130 (2001).</li> <li>23. Cappelleri, J. C., Gerber, R. A., Kourides, I. A. &amp; Gelfand, R. A. Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1 diabetes. <i>Diabetes Care</i> 23, 1799–1803 (2000).</li> <li>24. Oh. L-X. Hong, X. S. Sung, X. A. &amp; Barrett-Connor, E. Prevelance and factor analysis</li> </ul>
<ul> <li>(2009).</li> <li>Tibshirani, R. Regression shrinkage and selection via the lasso. J. R. Stat. Soc. 58, 267–288 (1996).</li> <li>Wei, H. et al. Environmental chemical exposure dynamics and machine learning-based prediction of diabetes mellitus. Sci. Total Environ. 806, 150674 (2022).</li> <li>Wold, S., Sjöström, M. &amp; Eriksson, L. PLS-regression: a basic tool of chemometrics. <i>Chemometrics Intellig. Lab. Syst.</i> 58, 109–130 (2001).</li> <li>Cappelleri, J. C., Gerber, R. A., Kourides, I. A. &amp; Gelfand, R. A. Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1 diabetes. <i>Diabetes Care</i> 23, 1799–1803 (2000).</li> <li>Oh, L-X. Hong, X. S. Sung, X. A. &amp; Barrett-Connor, E. Pravalence and factor analysis</li> </ul>
<ol> <li>Tibshirani, R. Regression shrinkage and selection via the lasso. J. R. Stat. Soc. 58, 267–288 (1996).</li> <li>Wei, H. et al. Environmental chemical exposure dynamics and machine learning-based prediction of diabetes mellitus. Sci. Total Environ. 806, 150674 (2022).</li> <li>Wold, S., Sjöström, M. &amp; Eriksson, L. PLS-regression: a basic tool of chemometrics. <i>Chemometrics Intellig. Lab. Syst.</i> 58, 109–130 (2001).</li> <li>Cappelleri, J. C., Gerber, R. A., Kourides, I. A. &amp; Gelfand, R. A. Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1 diabetes. <i>Diabetes Care</i> 23, 1799–1803 (2000).</li> <li>Oh, L-Y. Hong, Y. S. Sung, Y A. &amp; Barrett, Connor, E. Prevalence and factor analysis</li> </ol>
<ul> <li>288 (1996).</li> <li>21. Wei, H. <i>et al.</i> Environmental chemical exposure dynamics and machine learning-based prediction of diabetes mellitus. <i>Sci. Total Environ.</i> 806, 150674 (2022).</li> <li>22. Wold, S., Sjöström, M. &amp; Eriksson, L. PLS-regression: a basic tool of chemometrics. <i>Chemometrics Intellig. Lab. Syst.</i> 58, 109–130 (2001).</li> <li>23. Cappelleri, J. C., Gerber, R. A., Kourides, I. A. &amp; Gelfand, R. A. Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1 diabetes. <i>Diabetes Care</i> 23, 1799–1803 (2000).</li> <li>24. Oh. LeX. Hong, X. S. Sung, X. A. &amp; Barrett-Connor, E. Prevalence and factor analysis</li> </ul>
<ol> <li>Wei, H. <i>et al.</i> Environmental chemical exposure dynamics and machine learning-based prediction of diabetes mellitus. <i>Sci. Total Environ.</i> 806, 150674 (2022).</li> <li>Wold, S., Sjöström, M. &amp; Eriksson, L. PLS-regression: a basic tool of chemometrics. <i>Chemometrics Intellig. Lab. Syst.</i> 58, 109–130 (2001).</li> <li>Cappelleri, J. C., Gerber, R. A., Kourides, I. A. &amp; Gelfand, R. A. Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1 diabetes. <i>Diabetes Care</i> 23, 1799–1803 (2000).</li> <li>Oh, L-X. Hong, X. S. Sung, X - A. &amp; Barrett-Connor, E. Prevalence and factor analysis</li> </ol>
<ul> <li>prediction of diabetes mellitus. <i>Sci. Total Environ.</i> 806, 150674 (2022).</li> <li>22. Wold, S., Sjöström, M. &amp; Eriksson, L. PLS-regression: a basic tool of chemometrics. <i>Chemometrics Intellig. Lab. Syst.</i> 58, 109–130 (2001).</li> <li>23. Cappelleri, J. C., Gerber, R. A., Kourides, I. A. &amp; Gelfand, R. A. Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1 diabetes. <i>Diabetes Care</i> 23, 1799–1803 (2000).</li> <li>24. Oh. L.X. Hong, X.S. Sung, X - A. &amp; Barrett-Connor, E. Prevalence and factor analysis</li> </ul>
<ul> <li>Wold, S., Sjöström, M. &amp; Eriksson, L. PLS-regression: a basic tool of chemometrics. <i>Chemometrics Intellig. Lab. Syst.</i> 58, 109–130 (2001).</li> <li>Cappelleri, J. C., Gerber, R. A., Kourides, I. A. &amp; Gelfand, R. A. Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1 diabetes. <i>Diabetes Care</i> 23, 1799–1803 (2000).</li> <li>Oh. LY. Hong, Y. S. Sung, YA. &amp; Barrett-Connor, E. Prevalence and factor analysis</li> </ul>
<ul> <li><i>Chemometrics Intellig. Lab. Syst.</i> 58, 109–130 (2001).</li> <li>Cappelleri, J. C., Gerber, R. A., Kourides, I. A. &amp; Gelfand, R. A. Development and</li> <li>factor analysis of a questionnaire to measure patient satisfaction with injected and</li> <li>inhaled insulin for type 1 diabetes. <i>Diabetes Care</i> 23, 1799–1803 (2000).</li> <li>Oh. LX. Hong, X. S. Sung, XA. &amp; Barrett-Connor, E. Prevalence and factor analysis</li> </ul>
<ul> <li>23. Cappelleri, J. C., Gerber, R. A., Kourides, I. A. &amp; Gelfand, R. A. Development and</li> <li>factor analysis of a questionnaire to measure patient satisfaction with injected and</li> <li>inhaled insulin for type 1 diabetes. <i>Diabetes Care</i> 23, 1799–1803 (2000).</li> <li>24. Oh. LY. Hong, Y. S. Sung, YA. &amp; Barrett-Conner, F. Prevalence and factor analysis</li> </ul>
<ul> <li>factor analysis of a questionnaire to measure patient satisfaction with injected and</li> <li>inhaled insulin for type 1 diabetes. <i>Diabetes Care</i> 23, 1799–1803 (2000).</li> <li>Oh. LY. Hong, Y. S. Sung, YA. &amp; Barrett-Connor, E. Prevalence and factor analysis</li> </ul>
<ul> <li>inhaled insulin for type 1 diabetes. <i>Diabetes Care</i> 23, 1799–1803 (2000).</li> <li>Oh L-X Hong X S Sung X - A &amp; Barrett-Connor E Prevalence and factor analysis</li> </ul>
566 24 Oh L-V Hong V S Sung V-A & Barrett-Connor E Dravalance and factor analysis
$-2\pi$ . On, j1., mong, 1. 5., sung, 1A. & Daneu-Connor, E. FIEValence and factor allarysis
567 of metabolic syndrome in an urban Korean population. <i>Diabetes Care</i> <b>27</b> , 2027–2032
568 (2004).
569 25. Augstein, P. <i>et al.</i> Q-Score: development of a new metric for continuous glucose
570 monitoring that enables stratification of antihyperglycaemic therapies. <i>BMC Endocr</i> .
571 Disord. 15, 22 (2015).
572 26. Guo, W., Zhou, Q., Jia, Y. & Xu, J. Cluster and Factor Analysis of Elements in Serum
and Urine of Diabetic Patients with Peripheral Neuropathy and Healthy People. <i>Biol.</i>
574 Trace Elem. Res. <b>194</b> , 48–57 (2020).
575 27. Hall, H. <i>et al.</i> Glucotypes reveal new patterns of glucose dysregulation. <i>PLoS Biol.</i> <b>16</b> ,
576 e2005143 (2018).
577 28. De Gaetano, A. & Arino, O. Mathematical modelling of the intravenous glucose
578 tolerance test. J. Math. Biol. 40, 136–168 (2000).

- 579 29. Hulman, A. *et al.* Glucose patterns during an oral glucose tolerance test and associations
- with future diabetes, cardiovascular disease and all-cause mortality rate. Diabetologia 580 **61**, 101–107 (2018). 581
- 30. Cobelli, C. & Facchinetti, A. Yet Another Glucose Variability Index: Time for a 582 Paradigm Change? *Diabetes Technol. Ther.* **20**, 1–3 (2018). 583
- 31. Ceriello, A. et al. Oscillating glucose is more deleterious to endothelial function and 584
- oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 57, 585 1349–1354 (2008). 586
- 32. Lakka, H.-M. et al. The metabolic syndrome and total and cardiovascular disease 587 mortality in middle-aged men. JAMA 288, 2709-2716 (2002). 588
- 33. Rousseeuw, P. J. Silhouettes: A graphical aid to the interpretation and validation of 589
- cluster analysis. J. Comput. Appl. Math. 20, 53-65 (1987). 590